AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol

Infertility Clinical Trial

Official title:

AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01762111
• Other study ID #: OVO-12-22
• Status: Withdrawn
• Start date: December 2012
• Est. completion date: December 2013

Study information

• Verified date: January 2022
• Source: Clinique Ovo
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The woman fertility decrease with the age and there is a closely link with the ovarian reserve, the number of available eggs in the ovaries. Therefore, it is important to evaluate the ovarian reserve with specific marker to have a better prediction of the response of the in vitro fertilization treatment and to have a better rate of pregnancy.

Until now, a lot of clinical criteria (age, duration of the infertility, number of antral follicles) and biological (FSH, Oestradiol, Inhibin B, EFFORT test, number of the eggs at the retrieval day) was suggested to help for the estimation of the ovarian reserve.

Since couple of years, the anti-müllerian hormone (AMH) is recognize to be one of the best ovarian reserve marker, it corresponding the number of antral follicles, it is more sensitive and predictive. Moreover, during the In-Vitro Fertilization, the anti-müllerian hormone can provide the weak responds at the stimulation and the reverse, the risk of excessive responds (hyperstimulation). To choose the gonadotropin doses to administrate (stimulation ovarian hormone) during an In-Vitro Fertilization protocol, we need to know the anti-müllerian hormone dosage. However, if the anti-müllerian hormone is recognize to evaluate the quantity of available eggs in the ovaries, his role to determine the quality of these eggs still discussed.

The goal of this study is to verify if the serum anti-müllerian hormone (blood) is a good indicator for the quality of the reserve ovarian evaluating the impact of anti-müllerian hormone rate on the pregnancy rate and implantation rate, during stimulate In-Vitro Fertilization protocol.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 43 Years

Eligibility

Inclusion Criteria:

• All infertile patients aged between 18 and 43 years

• Patients with a prescription for a stimulated In-Vitro Fertilization cycle

Exclusion Criteria:

• Presence of endocrine disease: diabetes, hyperprolactinemia, abnormal thyroid-stimulating hormone (TSH) or Cushing syndrome

• Renal or hepatic impairment known

Related Conditions & MeSH terms

• Infertility

Locations

Country	Name	City	State
Canada	Clinique Ovo	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Clinique Ovo

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pregnancy rates	Clinical pregnancy rates per cycle and per transfer	7 weeks
Secondary	Cumulative pregnancy rates	Cumulative pregnancy rates including all frozen embryo transfer	5 years
Secondary	Number of eggs	Number of eggs retrieve at the end of the stimulated in-vitro fertilization cycle	4 weeks
Secondary	Number of embryos	Number of embryos obtain at the end of the stimulated in-vitro fertilization cycle	4 weeks